Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1 Inhibition Following CD30 CAR-T in Relapsed/Refractory Classical Hodgkin Lymphoma
NCT04134325Phase 1Active, not recruiting
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Sep 2019
- Primary completion
- Apr 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of nivolumab and pembrolizumab in classical Hodgkin lymphoma (cHL) (2 arms), sponsored by UNC Lineberger Comprehensive Cancer Center. Primary endpoint: Objective Response Rate at 12 weeks. Started Sep 2019; status: active, not recruiting.
02
Drugs
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT04134325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04134325.